Northwest & Ethical Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Northwest & Ethical Investments’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,187	Closed	-$669K	–	417
2022 Q1	$669K	Sell	1,187 -294	-20%	-$177K	0.02%	334
2021 Q4	$1.12M	Sell	1,481 -2,741	-65%	-$2.05M	0.03%	291
2021 Q3	$3.15M	Sell	4,222 -32	-0.8%	-$24K	0.1%	203
2021 Q2	$2.74M	Hold	4,254	–	–	0.09%	207
2021 Q1	$2.43M	Buy	+4,254	New	+$2.52M	0.09%	244
2020 Q3	–	Sell	-2,434	Closed	-$1.1M	–	402
2020 Q2	$1.1M	Buy	+2,434	New	+$1.07M	0.05%	296
2018 Q4	–	Sell	-200	Closed	-$62.6K	–	368
2018 Q3	$62.6K	Sell	200 -300	-60%	-$93.1K	﹤0.01%	347
2018 Q2	$144K	Sell	500 -100	-17%	-$27.6K	0.01%	337
2018 Q1	$150K	Buy	+600	New	+$153K	0.01%	331

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northwest & Ethical Investments's BIO Position: Q2 2022 in Review

Northwest & Ethical Investments sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 1,187 shares — an estimated $669K sold.

Northwest & Ethical Investments first reported a position in BIO in Q1 2018 and held it in 9 quarters. The position peaked at $3.15M in Q3 2021. 500 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

Northwest & Ethical Investments reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
Northwest & Ethical Investments sold 1,187 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $669K.
Northwest & Ethical Investments first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and held it in 9 quarters.
Northwest & Ethical Investments's Bio-Rad Laboratories Class A position peaked at $3.15M in Q3 2021.
500 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Northwest & Ethical Investments's 13F filing for Q2 2022, filed 9 Jul 2025.